From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Defense Pharmaceuticals for Nerve Agent Soman

by Global Biodefense Staff
March 4, 2014
Nerve and Blister Agent Protective Gear
Nerve and Blister Agent Protective Gear. Credit: USA.gov

The U.S. Department of Defense recently issued a Request for Information (RFI) to conduct market research for manufacturing capabilities for a nerve agent pretreatment for use by military personnel.

The military currently procures a pretreatment for use prior to exposure to the chemical nerve agent soman, as part of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP). Each tablet contains 30 mg of pyridostigmine bromide, as an orally active cholinesterase inhibitor, and is supplied in sealed blister or strip packaging within a protective sleeve.

The annual estimated quantity under the current contract is 36,000 blister packages containing 21 tablets each (or 756,000 tablets) per year. The current manufacturer of this product is Valeant Pharmaceuticals International.

System requirements include manufacturing capability to produce pyridostigmine bromide in the doses currently procured by the DoD, to include labeling, packaging and shipping configurations. The storage conditions and shelf life should be identical to. SNAPP.

The U.S. Army Office of The Surgeon General (OTSG) sponsors the SNAPP New Drug Application (NDA), approved in February 2003. It is anticipated that interested parties would become either a contract manufacturer under the OTSG NDA, or could potentially submit their own Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). 

This effort is managed by the Medical Countermeasure Systems – Chemical Defense Pharmaceuticals (MCS-CDP) Joint Product Management Office which is responsible for the development, procurement, fielding, and sustaining of medical treatment and prophylactic capabilities against chemical, radiological and nuclear threats.

Further details are available under Solicitation Number: W911QY14SCDP3. 

From Our Partners
Tags: JPEO-CBRNDRFI

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC